Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926062 | 0.94 | IDO1 (0.53) | TSHRIDO1CHRNA7ALDH1A1XBP1 | |
| SCHEMBL30422264 | 0.94 | IDO1 (0.53) | TSHRIDO1CHRNA7ALDH1A1XBP1 | |
| Hydrochloric Acid SCHEMBL28558644 | 0.92 | IDO1 (0.55) | TSHRIDO1ALDH1A1SIGMAR1XBP1 | |
| Methane SCHEMBL28634069 | 0.92 | IDO1 (0.52) | TSHRIDO1ALDH1A1XBP1HTT | |
| SCHEMBL30094172 | 0.85 | IDO1 (0.50) | IDO1PDPK1SIGMAR1 | |
| SCHEMBL1117278 | 0.85 | IDO1 (0.50) | IDO1PDPK1SIGMAR1 | |
| SCHEMBL29156852 | 0.79 | IDO1 (0.41) | TSHRIDO1PRCPALDH1A1SIGMAR1 | |
| SCHEMBL18716864 | 0.78 | TSHR (0.46) | TSHRIDO1PRCPCHRNA7PDPK1 | |
| SCHEMBL440138 | 0.77 | HTR2A (0.54) | IDO1PRCPPDPK1 | |
| SCHEMBL29793145 | 0.77 | HTR2A (0.54) | IDO1PRCPPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973882-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-6740661-B2 | TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS | SCHERING CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-6372747-B1 | ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1140902-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037459-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| EP-0575890-B1 | Fumaric acid salts of quinoline derivatives to overcome MDR in cancer treatment | MITSUI CHEMICALS INC (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5434155-A | FOR STIMULATION OF A CARCINOSTATIC EFFECT | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-07-18 | — | — | US | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0575890-A1 | Fumaric acid salts of quinoline derivatives to overcome MDR in cancer treatment | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-12-29 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | TSHR 1799/4885IDO1 4703/4885PRCP 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.